Agenus Reports Promising Results for Botensilimab-Balstilimab Combination in Treatment-Refractory Ovarian Cancer
核心洞察
Agenus published clinical results showing botensilimab plus balstilimab achieved a 23% overall response rate and 31% clinical benefit rate in heavily pretreated, treatment-refractory ovarian cancer (搜索) patients.
The combination demonstrated durable responses with a median duration of 9.7 months and median overall survival of 14.8 months in a population historically resistant to immunotherapy.
The study enrolled 44 women with treatment-refractory ovarian cancer (搜索), with nearly three-quarters being platinum-resistant or platinum-refractory patients.
Agenus Inc. has published promising clinical results from its Phase 1b C-800-01 trial evaluating the combination of botensilimab plus balstilimab (BOT+BAL) in treatment-refractory ovarian cancer (搜索), demonstrating meaningful activity in a patient population with historically poor outcomes. The peer-reviewed results, published in The Journal for ImmunoTherapy of Cancer, show the potential for this novel immunotherapy combination to address a significant unmet medical need.
Clinical Efficacy in Heavily Pretreated Population
The study enrolled 44 women with treatment-refractory ovarian cancer (搜索) who had received multiple prior lines of therapy. In this heavily pretreated population, BOT+BAL achieved a 23% overall response rate and 31% clinical benefit rate, with durable responses showing a median duration of 9.7 months. Median overall survival reached 14.8 months, with an estimated 75% of patients alive at 12 months.
Nearly three-quarters of the enrolled patients were platinum-resistant or platinum-refractory, representing a particularly challenging population with limited therapeutic options. Most patients had high-grade serous tumors (搜索), though responses were observed across multiple ovarian cancer (搜索) subtypes including high-grade serous, clear cell, and endometrioid tumors (搜索).
Notably, activity was demonstrated even in primary platinum-refractory patients—a rare and high-risk group often excluded from clinical studies. This finding is particularly significant given that therapy with first-generation checkpoint inhibitors has yielded modest responses in ovarian cancer (搜索), with objective response rates between 8-10% and median progression-free survival of roughly 2 months.
Addressing Critical Unmet Need
Ovarian cancer (搜索) represents a significant global health burden, causing approximately 13,000 deaths annually in the U.S. and 200,000 globally. Outcomes are particularly poor once tumors become platinum-resistant or platinum-refractory, leaving many women with rapidly diminishing treatment options and no approved immunotherapy combinations.
"These results offer a meaningful signal of clinical activity for women with platinum-refractory ovarian cancer (搜索), a group that has seen little therapeutic progress," commented Steven O'Day, MD, Chief Medical Officer at Agenus. "Botensilimab's unique immune activation profile translated into clinically significant responses in a population long considered resistant to immunotherapy."
Safety Profile and Tolerability
The BOT+BAL combination demonstrated a manageable and reversible safety profile, consistent with CTLA-4 (搜索) and PD-1 (搜索) therapy. The most common treatment-related adverse events included diarrhea/colitis (43%; 16% grade 3), fatigue and nausea (36%), which were effectively managed using established treatment guidelines. Importantly, no treatment-related deaths were reported in the study.
Mechanism of Action and Broader Development
Botensilimab is a human Fc enhanced multifunctional anti-CTLA-4 (搜索) antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to "cold" tumors which generally respond poorly to standard of care or are refractory to conventional PD-1 (搜索)/CTLA-4 therapies.
The drug works by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses. Balstilimab is a fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (搜索) from interacting with its ligands PD-L1 (搜索) and PD-L2 (搜索).
These findings build on results from the broader C-800-01 dataset presented at ESMO 2025, where BOT+BAL showed activity across multiple refractory solid tumors. Approximately 1,200 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials, with the combination showing clinical responses across nine metastatic, late-line cancers.
Clinical Implications and Future Directions
Rebecca Porter, M.D., Ph.D., from Dana-Farber Cancer Institute and lead author of the study, noted the significance of the findings: "These women faced some of the most treatment-resistant forms of ovarian cancer (搜索), yet several achieved meaningful and durable benefit. Seeing this level of activity in such a heavily pretreated population is encouraging and provides important insights to the field regarding therapy approaches for patients with very limited remaining options."
The results strengthen confidence in BOT+BAL's potential and support moving this combination into larger, randomized studies. BOT+BAL continues to advance through global clinical development across multiple tumor types, with eligible patients potentially able to access the combination through regulatory-authorized early access mechanisms in select countries.
The C-800-01 study (NCT03860272) is an ongoing, multicenter Phase 1b clinical trial that has enrolled over 400 patients with refractory disease across tumor types with limited or no responsiveness to prior checkpoint inhibitors. The collective data reinforce the potential of BOT+BAL to generate meaningful immune responses in cancers historically considered unresponsive to immunotherapy.